C82.6A
Cutaneous follicle center lymphoma, in remission
Clinical Classification Guidelines
Medical Intelligence & Overview
Cutaneous follicle center lymphoma (CFCL) is a type of skin lymphoma that originates from the follicle center cells of the lymphatic system. When this lymphoma is in remission, it means that the signs and symptoms have significantly decreased or are no longer detectable due to treatment. The ICD-10 code C82.6A specifically signifies that the lymphoma has entered a remission phase, which is a positive development in the management of the disease. This condition primarily affects the skin and is considered a type of non-Hodgkin lymphoma.
Causes & Symptoms
Clinical Causes: The exact cause of CFCL is unknown, but it involves abnormal growth of B-lymphocytes (a type of white blood cell) within the skin. Genetic mutations may play a role in the uncontrolled proliferation of lymphocytes. Certain environmental factors, such as exposure to specific chemicals or radiation, could potentially contribute to the development, although evidence is limited. A weakened immune system might increase susceptibility to lymphomas, including CFCL.
Key Symptoms: Develops as painless, red or brownish patches, plaques, or nodules on the skin. Lesions are often localized but can spread over time. The affected areas typically do not cause discomfort or pain, but some individuals might experience mild itching or irritation. Lesions may persist over months or years with little change in appearance, or occasionally, they may regress temporarily.
Diagnostic & Treatment
Diagnosis Path: Diagnosing CFCL involves a combination of clinical examination and laboratory tests. A dermatologist will examine the skin lesions and may perform a skin biopsy, where a small sample of affected skin is taken and examined microscopically. Additional tests such as immunohistochemistry and molecular studies help confirm the presence of lymphoma cells. Staging work-up, which may include imaging studies like PET scans or CT scans, helps determine if the disease has spread beyond the skin and to assess remission status.
Treatment Protocols: Treatment options for CFCL in remission vary depending on individual cases and disease progression. Common approaches include:
Clinical Advice & FAQs
Billing Guidance
Is C82.6A a billable ICD-10 code?
Yes, C82.6A is a specific, billable code that can be used to indicate a diagnosis for reimbursement purposes.
Documentation
How do I report C82.6A?
Clinical documentation must specify the nature of Cutaneous follicle center lymphoma, in remission and any associated comorbidities for accurate reporting.
Cite this Clinical Reference